Zanvastro is a drug owned by Ionis Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 20, 2041. Details of Zanvastro's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11786546 | Compounds And Methods For Modulating Gfap |
May, 2041
(14 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Zanvastro is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Zanvastro's family patents as well as insights into
ongoing legal events
on those patents.
Zanvastro's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zanvastro's generic launch date based on the expiry of its last outstanding patent is estimated to be May 20, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zanvastro Generics:
There are no approved generic versions for Zanvastro as of now.
About Zanvastro
Zanvastro is a drug owned by Ionis Pharmaceuticals Inc. Zanvastro uses Zilganersen Sodium as an active ingredient. Zanvastro was launched by Ionis in 2026.
Approval Date:
Zanvastro was approved by FDA for market use on 03 September, 2026.
Active Ingredient:
Zanvastro uses Zilganersen Sodium as the active ingredient. Check out other Drugs and Companies using Zilganersen Sodium ingredient
Dosage:
Zanvastro is available in solution form for intrathecal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML) | SOLUTION | Prescription | INTRATHECAL |